Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV
Authors:
Open Access
- 13 June 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 76 (9) , 2380-2393
Abstract
Switching from boosted PIs to dolutegravir in people living with HIV (PLWH) with high cardiovascular risk improved plasma lipids at 48 weeks in the NEAT022 trial. Whether this strategy may have an impact on cardiovascular biomarkers is unknown. We assessed 48 week changes in biomarkers associated with inflammation, endothelial dysfunction, monocyte immune activation, oxidation, insulin resistance, hypercoagulability, heart failure, myocardial injury, and glomerular and tubular kidney injury. Of 415 PLWH randomized in the NEAT022 study, 313 (75.4%) remained on allocated therapy and had paired samples available. Soluble CD14 (–11%, P < 0.001) and adiponectin (–11%, P < 0.001) significantly declined and high-sensitive C-reactive protein (–13%, P = 0.069) and oxidized LDL (–13%, P = 0.084) tended to decrease with dolutegravir. Switching to dolutegravir remained significantly associated with soluble CD14 and adiponectin reductions after adjustment for baseline variables. There were inverse correlations between soluble CD14 and CD4 count changes (P = 0.05), and between adiponectin and BMI changes (P < 0.001). Switching from boosted PIs to dolutegravir in PLWH with high cardiovascular risk led to soluble CD14 and adiponectin reductions at 48 weeks. While decreasing soluble CD14 may entail favourable health effects in PLWH, adiponectin reduction may reflect less insulin sensitivity associated with weight gain.Keywords
Funding Information
- NEAT-ID Foundation
- SSAT and ViiV Healthcare
- Spanish centres and Spanish (PI16/01085, RD12/0017)
- Plan Nacional I + D+i and co-funded by the Spanish Instituto de Salud Carlos III (ISCIII) – Subdirección General de Evaluación and European Regional Development Fund
This publication has 46 references indexed in Scilit:
- Soluble CD14Arteriosclerosis, Thrombosis, and Vascular Biology, 2013
- Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavirAIDS, 2012
- Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV InfectionThe Journal of Infectious Diseases, 2011
- Changes in Inflammatory and Coagulation Biomarkers: A Randomized Comparison of Immediate versus Deferred Antiretroviral Therapy in Patients With HIV InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
- Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL studyAIDS, 2010
- Markers of Inflammation, Coagulation, and Renal Function Are Elevated in Adults with HIV InfectionThe Journal of Infectious Diseases, 2010
- Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti‐HIV Drugs (D:A:D) StudyThe Journal of Infectious Diseases, 2010
- Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatmentAIDS, 2009
- Circulating adiponectin levels associate with inflammatory markers, insulin resistance and metabolic syndrome independent of obesityInternational Journal of Obesity, 2008
- Human Immunodeficiency Virus Protease Inhibitor Ritonavir Inhibits Cholesterol Efflux from Human Macrophage-Derived Foam CellsThe American Journal of Pathology, 2007